異基因造血干細(xì)胞移植治療多發(fā)性骨髓瘤ppt課件

1、Allogeneic haematopoietic cell transplantation for multiplemyelomanThe allogeneic transplant has the advantage over the autologous transplantnThe graft does not contain tumor cells and the potential for a graft versus myeloma (GvM) effectBone marrow transplantation in three patients with multiple my

2、eloma Gahrton G, Ringdn O, Lnnqvist B, Lindquist R, Ljungman P.Acta Med Scand 1986;219(5):523-7.瑞典卡羅林斯卡醫(yī)學(xué)院瑞典卡羅林斯卡醫(yī)學(xué)院 1983Myeloablative conditioning n Three patients with multiple myeloma received bone marrow grafts from HLA-identical sibling donorsn One of the patients, with IgA kappa myeloma, refra

3、ctory to alkeran-prednisone therapy, is well and still without sign of disease 26 months post transplantationn A second patient with Bence-Jones kappa myeloma is well, and skeletal pain and Bence-Jones proteinuria has disappeared 2 months after transplantation.n A third patient with IgG-lambda myelo

4、ma died of effusive pericarditis shortly after transplantation. Acta Med Scand 1986;219(5):523-7Conclusion n Bone marrow transplantation may be indicated in a selective group of patients with multiple myelomaActa Med Scand 1986;219(5):523-7n Out of 690 allogenetic matched sibling donor transplants f

5、or MM n344 were performed during the period 1983-93(all with BM ) group 1n356 during 1994-98 (223 with BM group 2 and 133 with PB group 3)u the median age at transplantation of patients in group 1 was 43 years (range 21-62)uIn group 2 ,44 years (range 18_57) and in group 3, 46 years (range 25_60)u T

6、BI+CY tended to be more commonly used in group 1(37%) and 2 (39%) than in group 3 (27%)uMelphalan containing regimes tended to be morely used in group 3 uMelphalan or Busulphan + CY rarely nConditiong regimeEngraftmentGVHD Treatment related mortalityTreatment related mortalityRelapse rate Relapse ra

7、te SurvivalSurvivalnProgression free survivalu PFS was significantly better for group 2than for group 1(P0.0001)uWith no significantly difference between group 2 and 3nCause of death u 75% in group 1,36% in group 2 ,33 % in group 3 uGVHDuFungal uARDSuOrgan failurenCause of death u the study shows th

8、at the improvement is entirely a result of a lower TRM during the latest 5-years periodu aGVHD has no changed during this peroid uThere was significant difference in deaths caused by IP and bacterial and fungalinfectionConditioning regime u TBI+Melphalan has not previrous been u Shown to be superior

9、 to TBI+CY in this studynconclusion n Survival n 3060%nTreatment related mortalityn30%Myeloablative allogeneic versus autologous transplantationnduring the years 1983 to 1994n189 myeloma patients who underwent allo-BMT with an HLA-identical sibling donor were compared retrospectively with an equal n

10、umber of patients who receivedn a single autologous bone marrow or blood stem cell graftnAnd the ASCT patients were transplanted from 1986 to 1994n conclusionn The overall survival was significantly better for ASCT than for allo-BMT, with a median survival of 34 months and 18 months, respectively (P

11、 = .001), n The main reason for the poorer survival in allo-BMT patients was higher TRM (41% v 13% for ASCT, P = .0001), which was not compensated for by a lower rate of relapse and progressionn conclusionnHowever, in patients alive at 1 year posttransplant, there was a trend for better long-term su

12、rvival (P = .O9) and significantly better progression-free survival (P = .02) for allo-BMT as compared with ASCTnWe conclude that the median survival is superior for ASCTnHowever, allo-BMT has a lower relapse rate, which results in a similar long-term outcome for both approaches, but a longer follow

13、-up is needed to assess the final outcome Reduced-intensity conditioning allogeneic transplantationnThe Allo-RIC was introduced in an attempt to decrease the transplant-related toxicity while retaining the beneficial GvM effectn2019 begin clinical studyn 20192019nWe report the outcome of 229 patient

14、snwho received an allograft for myelomanwith reduced-intensity conditioning (RIC)nregimens from 33 centers within the EBMT.n With a median follow-up of 28 months, 115 patients are alive(range, 1-53 months)n The estimated overall survival at 3 yearsn is 40.6% (CI, 33%-49%) n The treatment-related mor

15、talities at day 100, 1 year,and 2 years were 10%, 22%, and 26%, respectively.n The cumulative probability of the progression-free survival was 21.3% (CI, 15%-29%) at 3years Conclusion While RIC is feasible, heavily pretreated patients and patients with progressive disease do not benefit RIC vs MACnD

16、ata were available on a total of 516 patients from 103 centers: 320 patients with RIC and 196 with MAC.nbetween January 1, 2019, to December 31, 2019nThe median follow-up was 28 monthsnconclusionn RIC was associated with a reduction in TRM but this was offset by an increase in relapse risk nthe cond

17、itioning intensity did not impact on overall survival or retain significance for PFSnThese data suggest that there is a continuing need to investigate dose intensity in the conditioning for myeloma allografts.Tandem autologous/Allo-RIC transplantationn Autologous hematopoietic cell transplantation(H

18、CT) followed by nonmyeloablative allogeneic HCT (auto/alloHCT) provides cytoreduction and graft-versus-myeloma effects. 弗雷德哈欽森癌癥研討中心弗雷德哈欽森癌癥研討中心n Patient inclusion criteria for this analysis were nstage II or III MM at diagnosisn available human leukocyte antigen (HLA)identical sibling donorn progra

19、mmed sequential treatment with conventional autologous HCT followed by nonmyeloablative auto/alloHCT nno prior autologous HCT.n 105 patients with MM fulfilling those criteria were sequentially enrolled at 10 centers on 4 FHCRC-coordinated multiinstitutional protocols from August 2019 to August 2019n

20、 Patients proceeded to allogeneic HCT 40 to 180 days after autograftingn Autologous HCT.n(G-CSF) mobilized peripheral blood mononuclear cells (G-PBMC) were harvested by leukapheresis after treatment with cyclophosphamide 3 to 4 g/m2 (day 1) and G-CSF 10 g/kg subcutaneously (from day 3 through collec

21、tion)n Autologous HCTn38 patients received additional paclitaxel (250 mg/m2 per day, day 2),nand 25 received additional etoposide (200 mg/m2 per day; days 1, 2, 3) nand dexamethasone (10 mg/day orally; days 1, 2,3, 4)nTwo patients received G-CSF alone.n Autologous HCTnNo treatment for MM was given b

22、etween autologous and allogeneic HCTn Allogeneic HCTn After recovery from autologous HCTn102 patientsproceeded to allotransplantation. Donors were HLA-identical siblingsn Nonmyeloablative conditioning consisted in all patients of 2 Gy total body irradiation (TBI) at 7 cGy/min by linear accelerator o

23、r cobalt on day 0n27 patients received additional fludarabine (30 mg/m2) on days 4, 3, and 2N%n EngraftmentnAll 102 allografted patients had sustained engraftment. nOn day 28, medians of 90%, 95%, and 95% of peripheral blood T cells, granulocytes, and nucleated marrow cells,respectively, were of don

24、or origin.nThis increased to medians of 96% to 100% on day 84GVHD43 patients (42%) developed grades 2 to 4 acute GVHD at a median of 42 (range, 8-107) days74 patients (74%) developed chronic extensive GVHD at a median of 167 (range, 90-830) days after transplantation.n NRMnNRM was 1% at day 100 and

25、11%, 14%, and 18% at 1, 2, and 5 years after allografting, respectivelynGVHD and infections were responsible for 18 of 19 non relapse related deaths.n Overall and progression-free survivalsnAfter a median follow-up of 6.3 years after allografting (range 2-9)n60 of 102 (59%)patients survived and 33 o

26、f 102 (32%) are in remissionnFive-year estimated OS and PFS were 64% and 36%,respectivelyn conclusionnauto/allo-RIC HCT is a treatment option for patients with advanced stage MMnThe addition of novel agents (eg,thalidomide, bortezomib, and lenalidomide) as induction or postgrafting therapy, acting w

27、ith GVM effects against disease-specific antigens, might further improve the outcome.n improve the outcomenThalidomide/lenalidomidendexamethasonenBortezomib研討所佩奧利研討所佩奧利- Calmettes，馬賽，法國(guó)，馬賽，法國(guó) n This was a retrospective study from 3 centers n 37 patients treated between November 2019 and March 2019n conclusionnbortezomib is a safe and efficient option for myeloma patients after RIC-allo-SCT. Double autologous Versus tandem auto/Allo-RIC transplantation圣喬凡尼巴蒂斯塔大學(xué)醫(yī)院，都靈，意大利圣喬凡尼巴蒂斯塔大學(xué)醫(yī)院，都靈，意大利 n